Nevro Corp. (NVRO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nevro Corp. (NVRO) trades at $5.84 with AI Score 48/100 (Grade C). Nevro Corp. develops and commercializes neuromodulation solutions for chronic pain. Market cap: $224.09M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for NVRO: NVRO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVRO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NVRO: the 1 perspectives are evenly split.
How is this calculated? →Nevro Corp. (NVRO) Healthcare & Pipeline Overview
Nevro Corp. specializes in neuromodulation technology for chronic pain, primarily through its Senza spinal cord stimulation system. With a focus on 10 kHz Therapy, the company addresses a significant market need, distributing its products via direct sales and partnerships in the United States and internationally.
What Is the Investment Thesis for NVRO?
Nevro Corp. presents a compelling investment case based on its innovative Senza spinal cord stimulation system and its focus on the chronic pain market. The company's 10 kHz Therapy offers a differentiated approach to pain management, supported by clinical evidence. However, with a market cap of $224.09M and a negative profit margin of -27.8%, investors should carefully consider the financial risks. Key growth catalysts include expanding market penetration in the United States and internationally, as well as continued innovation in neuromodulation technology. The company's gross margin of 66.0% indicates strong pricing power, but profitability needs improvement. Monitoring the company's ability to manage costs and achieve profitability is crucial for assessing its long-term value.
Based on FMP financials and quantitative analysis
NVRO Key Highlights
- Market Cap of $224.09M reflects the company's current valuation in the market.
- Gross Margin of 66.0% demonstrates strong pricing power and efficient production.
- Profit Margin of -27.8% indicates ongoing challenges in achieving profitability.
- Beta of 0.82 suggests lower volatility compared to the overall market.
- Nevro's focus on 10 kHz Therapy provides a differentiated approach to chronic pain management.
Who Are NVRO's Competitors?
NVRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDT Medtronic plc | $83.83 | +0.93% | $107.31B | 77 |
| BSX Boston Scientific Corporation | $45.23 | +1.42% | $67.24B | 82 |
| DCTH Delcath Systems, Inc. | $13.48 | +0.00% | $465.35M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +0.00% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.59 | -3.75% | $718.47M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| AXGN AxoGen, Inc. | $45.33 | -1.39% | $2.41B | 58 |
| AXNX Axonics, Inc. | $70.98 | +0.00% | $3.63B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVRO's Key Strengths?
- Innovative 10 kHz Therapy.
- Strong clinical evidence.
- Established distribution network.
- Advanced Senza Omnia system.
What Are NVRO's Weaknesses?
- Negative profit margin.
- Limited product diversification.
- High reliance on spinal cord stimulation.
- Smaller market share compared to larger competitors.
What Could Drive NVRO Stock Higher?
- Publication of new clinical data supporting the efficacy of 10 kHz Therapy.
- Expansion of the sales force to increase market penetration in key regions.
- Development and launch of next-generation neuromodulation systems.
- Regulatory approvals for new indications and product enhancements.
What Are the Key Risks for NVRO?
- Financial-distress signal — its Altman Z-Score of -0.60 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-43.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with greater resources.
- Regulatory changes and reimbursement pressures affecting pricing and market access.
- Economic downturns leading to reduced healthcare spending.
- Product liability claims and recalls impacting brand reputation.
What Are the Growth Opportunities for NVRO?
- Expansion in International Markets: Nevro has the opportunity to expand its presence in international markets, particularly in Europe and Asia-Pacific. These regions have a growing aging population and increasing awareness of chronic pain management solutions. By establishing strategic partnerships and expanding its distribution network, Nevro can tap into these markets and drive revenue growth. The global market for spinal cord stimulation devices is expected to grow, offering a substantial opportunity for Nevro to increase its international sales.
- Product Innovation and Development: Continued investment in research and development is crucial for Nevro to maintain its competitive edge. Developing new and improved neuromodulation technologies, such as advanced spinal cord stimulation systems and therapies for other chronic pain conditions, can attract new customers and increase market share. Innovation in areas like closed-loop stimulation and personalized therapy could further differentiate Nevro's offerings and drive adoption.
- Strategic Partnerships and Acquisitions: Nevro can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other medical device companies or acquiring complementary technologies can enhance Nevro's offerings and provide access to new markets. For example, partnering with a company specializing in pain diagnostics could improve patient selection and treatment outcomes, driving adoption of Nevro's Senza system.
- Increased Awareness and Adoption of 10 kHz Therapy: Nevro can focus on increasing awareness and adoption of its 10 kHz Therapy among physicians and patients. By conducting clinical trials, publishing research papers, and educating healthcare providers about the benefits of 10 kHz Therapy, Nevro can drive adoption of its Senza system. Increased awareness can lead to greater patient demand and higher sales volumes, contributing to revenue growth.
- Expansion into New Pain Management Areas: Nevro can explore opportunities to expand its neuromodulation technology into new pain management areas beyond spinal cord stimulation. This could include developing therapies for peripheral nerve stimulation, sacral nerve stimulation, or other chronic pain conditions. By diversifying its product portfolio, Nevro can reduce its reliance on spinal cord stimulation and tap into new markets, driving long-term growth.
What Opportunities Does NVRO Have?
- Expansion into international markets.
- Development of new neuromodulation technologies.
- Strategic partnerships and acquisitions.
- Increased awareness of 10 kHz Therapy.
What Threats Does NVRO Face?
- Competition from larger medical device companies.
- Regulatory changes and reimbursement pressures.
- Technological advancements by competitors.
- Economic downturns affecting healthcare spending.
What Are NVRO's Competitive Advantages?
- Proprietary 10 kHz Therapy technology.
- Strong clinical evidence supporting the efficacy of Senza system.
- Established distribution network in the United States and internationally.
- Brand recognition and reputation in the neuromodulation market.
What Does NVRO Do?
Nevro Corp., founded in 2006 and headquartered in Redwood City, California, is a medical device company focused on providing innovative solutions for chronic pain management. The company's core product is the Senza spinal cord stimulation (SCS) system, a neuromodulation platform designed to alleviate chronic pain through its unique 10 kHz Therapy. This therapy delivers electrical pulses to the spinal cord, modulating nerve activity and reducing pain signals. The Senza system includes the Senza II and Senza Omnia systems, offering advanced features and customization options to meet individual patient needs. Nevro distributes its products through a direct sales force in the United States and through a network of sales agents and independent distributors internationally, ensuring broad market access. The company's commitment to evidence-based medicine is reflected in its rigorous clinical trials and data-driven approach to product development, positioning it as a key player in the neuromodulation space. Nevro continues to innovate and expand its product offerings to address the diverse needs of patients suffering from chronic pain, solidifying its presence in the global medical device market.
What Products and Services Does NVRO Offer?
- Develops and commercializes the Senza spinal cord stimulation (SCS) system.
- Offers 10 kHz Therapy for chronic pain management.
- Provides the Senza II and Senza Omnia systems for advanced neuromodulation.
- Distributes products through a direct sales force in the United States.
- Utilizes a network of sales agents and independent distributors internationally.
- Focuses on evidence-based neuromodulation solutions.
- Addresses chronic pain conditions through innovative medical devices.
How Does NVRO Make Money?
- Develops and manufactures spinal cord stimulation systems.
- Sells SCS systems and related accessories to hospitals and clinics.
- Provides training and support to healthcare professionals.
- Generates revenue through direct sales and distribution partnerships.
What Industry Does NVRO Operate In?
The medical device industry, particularly the neuromodulation segment, is experiencing growth driven by an aging population and increasing prevalence of chronic pain. The market is competitive, with major players like Medtronic and Boston Scientific also offering spinal cord stimulation devices. Nevro's focus on 10 kHz Therapy differentiates it from competitors, offering a unique approach to pain management. The industry is subject to regulatory scrutiny and requires significant investment in research and development. The global pain management devices market is projected to reach billions of dollars in the coming years, presenting significant opportunities for companies like Nevro.
Who Are NVRO's Key Customers?
- Hospitals and clinics specializing in pain management.
- Physicians who treat patients with chronic pain.
- Patients suffering from chronic pain conditions.
- Healthcare providers seeking neuromodulation solutions.
ROE -43%Key Financial Metrics
Return on equity for Nevro Corp. stands at -43.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.4%, the inverse of the P/E and a quick read on earnings relative to price.
Nevro Corp. (NVRO) Valuation Context
Valued at $224.09M, NVRO is classified as a micro-cap stock. Relative to its peer group, NVRO's quantitative score of 48/100 is below the peer average of 75/100.
Company Profile
Nevro Corp. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Kevin R. Thornal. NVRO has traded publicly since 2014.
F-Score 2/9Financial Health
Nevro Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.60 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Nevro Corp. revenue of about $423.7M for fiscal 2026, with EPS near $-2.09. The estimate reflects 8 contributing analysts.
NVRO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal strong confidence in Nevro's future prospects, suggesting they believe the company is undervalued.
- Community sentiment appears optimistic about Nevro's long-term growth potential, driven by positive discussions around new product developments.
- The market seems to be recognizing Nevro's potential in addressing chronic pain, leading to increased investor interest.
- Nevro's focus on innovation in spinal cord stimulation is resonating well, positioning them favorably against competitors.
Bear Case
- Some insiders may be selling shares for personal financial reasons, which doesn't necessarily reflect negatively on the company, but warrants attention.
- A segment of the community expresses concerns about Nevro's ability to scale effectively and maintain its competitive edge.
- Market perception of Nevro could be influenced by broader healthcare sector trends, leading to volatility unrelated to the company's performance.
- There are bearish arguments circulating about the long-term efficacy and adoption rates of spinal cord stimulation therapies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NVRO Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Jan 25, 2022
NVRO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVRO.
Price Targets
Wall Street price target analysis for NVRO.
NVRO MoonshotScore
What does this score mean?
The MoonshotScore rates NVRO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin R. Thornal
Chief Executive Officer
Kevin R. Thornal serves as the Chief Executive Officer of Nevro Corp. His career spans various leadership roles within the medical device industry, bringing extensive experience in strategic planning, commercial operations, and product development. Before joining Nevro, Thornal held key positions at leading healthcare companies, contributing to the growth and success of innovative medical technologies. His background includes a strong focus on market access, sales effectiveness, and driving adoption of novel therapies. Thornal's expertise is instrumental in guiding Nevro's strategic direction and expanding its market presence.
Track Record: Since assuming the role of CEO, Kevin R. Thornal has focused on enhancing Nevro's commercial strategy and driving adoption of the Senza system. He has overseen efforts to expand the company's market reach, improve sales efficiency, and strengthen relationships with healthcare providers. Under his leadership, Nevro has continued to innovate and develop new neuromodulation technologies. Thornal's strategic decisions have been aimed at positioning Nevro for long-term growth and success in the competitive medical device market.
Nevro Corp. Healthcare Stock: Key Questions Answered
What does Nevro Corp. do?
Nevro Corp. is a medical device company specializing in neuromodulation solutions for chronic pain. Its primary product is the Senza spinal cord stimulation (SCS) system, which utilizes a proprietary 10 kHz Therapy to deliver pain relief. The Senza system includes the Senza II and Senza Omnia systems, offering advanced features and customization options. Nevro distributes its products through a direct sales force in the United States and a network of sales agents and independent distributors internationally, focusing on providing evidence-based solutions for patients suffering from chronic pain.
What do analysts say about NVRO stock?
Analyst consensus on NVRO stock reflects a mixed outlook, with some highlighting the company's innovative 10 kHz Therapy and growth potential in the chronic pain market. Key valuation metrics, such as price-to-sales ratio and enterprise value-to-EBITDA, are closely monitored. Growth considerations include the company's ability to expand market share, improve profitability, and successfully launch new products. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for NVRO?
The main risks for Nevro Corp. include competition from larger medical device companies, regulatory changes and reimbursement pressures, and economic downturns affecting healthcare spending. Competition from companies like Medtronic and Boston Scientific, with greater resources and broader product portfolios, poses a significant challenge. Regulatory changes and reimbursement policies can impact pricing and market access. Economic downturns may lead to reduced healthcare spending, affecting demand for Nevro's products. Product liability claims and recalls can also impact brand reputation and financial performance.
How does Nevro Corp. navigate regulatory approval processes?
Nevro Corp. navigates regulatory approval processes through rigorous clinical trials and adherence to regulatory standards. The company works closely with regulatory agencies such as the FDA in the United States to ensure compliance with safety and efficacy requirements. Nevro's track record includes successful FDA approvals for its Senza spinal cord stimulation system and related products. The company's regulatory strategy involves comprehensive documentation, proactive communication with regulatory bodies, and a commitment to meeting all applicable standards. Pending approvals are closely monitored, and Nevro maintains a robust compliance program to ensure ongoing adherence to regulatory requirements.
How does Nevro Corp.'s technology compare to other pain management solutions?
Nevro Corp.'s 10 kHz Therapy offers a differentiated approach to pain management compared to traditional low-frequency spinal cord stimulation. The 10 kHz Therapy is designed to provide superior pain relief without paresthesia, a common side effect of traditional SCS. Clinical studies have shown that Nevro's technology can lead to better outcomes and improved quality of life for patients with chronic pain. While other pain management solutions, such as medication and physical therapy, may provide temporary relief, Nevro's neuromodulation technology offers a long-term solution by directly modulating nerve activity and reducing pain signals.
What are the key factors to evaluate for NVRO?
Nevro Corp. (NVRO) holds an AI score of 48/100 (low). Not financial advice.
How frequently does NVRO data refresh on this page?
NVRO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NVRO's recent stock price performance?
Nevro Corp. (NVRO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative 10 kHz Therapy. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent reporting period.